Clinical Trial NCT03531255

Trial

Apellis – APL2-307

Clinical trial ID

NCT03531255

Drug name

APL-2 Pegcetacoplan

Company:

Apellis

Drug trade name

Empaveli® Aspaveli®

Phase of study

3

Current status

Active, not recruiting

Start

08/2018

Substance

Cyclopeptide

Research question

Long-term evaluation

Delivery method of drug

s.c.

Frequency

2 x weekly

Clinical trial locations

tralia Belgium Bulgaria Canada France Germany Hong Kong Japan Malaysia Russia Serbia Singapore South Korea Spain Thailand UK USA